AtriCure Inc.  

(Public, NASDAQ:ATRC)   Watch this stock  
Find more results for ATRC
+0.44 (2.54%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.05 - 17.89
52 week 13.19 - 23.00
Open 17.61
Vol / Avg. 111,461.00/160,293.00
Mkt cap 481.49M
P/E     -
Div/yield     -
EPS -0.67
Shares 27.47M
Beta 0.76
Inst. own 90%
Dec 3, 2014
AtriCure Inc at Piper Jaffray Healthcare Conference - 11:00AM EST - Add to calendar
Nov 20, 2014
AtriCure Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 18, 2014
AtriCure Inc at Stifel Healthcare Conference
Oct 30, 2014
Q3 2014 AtriCure Inc Earnings Call - Webcast
Oct 30, 2014
Q3 2014 AtriCure Inc Earnings Release
Sep 4, 2014
AtriCure Inc at Barrington Research Fall Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1.75% -14.00%
Operating margin -3.01% -13.30%
EBITD margin - -10.83%
Return on average assets -1.19% -15.88%
Return on average equity -1.39% -26.94%
Employees 320 -
CDP Score - -


6217 Centre Park Drive
United States - Map
+1-513-7554107 (Phone)
+1-513-7554108 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AtriCure, Inc. is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage. In January 2014, the Company announced that it has completed the acquisition of Endoscopic Technologies, Inc. d/b/a Estech.

Officers and directors

Richard M. Johnston Independent Chairman of the Board
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael H. Carrel President, Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
M. Andrew Wade CPA Chief Financial Officer, Vice President
Age: 39
Bio & Compensation  - Reuters
Douglas J. Seith Senior Vice President - Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Andrew L. Lux Ph.D. Senior Vice President - R&D, Operations and QA
Age: 62
Bio & Compensation  - Reuters
Patricia J. Kennedy Vice President, General Manager - International
Age: 53
Bio & Compensation  - Reuters
Michael D. Hooven Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark A. Collar Independent Director
Age: 61
Bio & Compensation  - Reuters
Scott William Drake Independent Director
Age: 46
Bio & Compensation  - Reuters
Elizabeth D. Krell Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters